Semaglutide (5mg)

What is Semaglutide (5 mg)?

Semaglutide (5 mg) is a long-acting synthetic peptide commonly studied in metabolic and endocrine research. It is a modified version of human glucagon-like peptide-1 (GLP-1), a natural hormone that plays a key role in glucose-dependent insulin signaling and metabolic regulation.

This peptide has specific amino acid substitutions and a fatty acid side chain that enhance its stability and prolong its receptor-binding duration in experimental systems. These modifications enable investigation of prolonged GLP-1 receptor interactions in model systems, which would not be possible with native GLP-1 due to its rapid degradation in the body.

Product Specifications

• CAS Number: 910463-68-2
• Synonym: NN9535
• Peptide Sequence:
  H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-OH
• Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
• Molecular Weight:6 g/mol
• Purity: ≥95% (verified by HPLC and mass spectrometry)
• Packaging Format: 5 mg lyophilized powder in sealed research-grade vial
• Storage Conditions: Store 2–8 °C (≤–20 °C long term). Protect from light.
• Intended Use: For Laboratory Research Use Only

Key Characteristics of Semaglutide (5 mg)

• Synthetic GLP-1 receptor agonist analog designed for research use
• Modified structure for enhanced stability in experimental systems
• Fatty acid side chain supports prolonged receptor interaction in laboratory models
• High analytical purity verified by HPLC and mass spectrometry
• Supplied as a lyophilized powder to preserve peptide integrity prior to reconstitution
• Suitable for endocrine, metabolic, and receptor-signaling research
• Compatible with standard peptide reconstitution and handling procedures

How Semaglutide (5 mg) Supports Research

Semaglutide (5 mg) is used in research to study GLP-1 receptor signaling and its effects on metabolic pathways. Researchers use this peptide to assess receptor binding, intracellular signaling (such as cAMP-related pathways), and hormone-regulated cellular responses under controlled conditions.

Thanks to its structural modifications, Semaglutide offers extended activity compared to natural GLP-1, enabling the investigation of prolonged receptor interactions and regulatory feedback mechanisms. It is commonly used in cellular models, tissue systems, and preclinical research to investigate endocrine communication and metabolic regulation.

Research Applications & Usage Information

Semaglutide (5 mg) is commonly used in laboratory and preclinical research focused on:

• GLP-1 receptor activation studies
• Glucose metabolism and insulin signaling pathway research
• Endocrine communication and hormone-receptor interaction studies
• Metabolic regulation pathway analysis
• Cellular second-messenger pathway investigation
• Comparative studies of incretin-based peptide analogs
• Pharmacokinetic and pharmacodynamic modeling in controlled systems

All applications are investigational and limited to controlled laboratory environments.

Handling and Storage Recommendations

• Store at 2–8 °C (≤–20 °C for long-term storage). Protect from light.
• Keep the vial sealed until ready for reconstitution.
• Minimize exposure to moisture and environmental contaminants.
• Allow the vial to equilibrate before opening to reduce condensation.
• After reconstitution, store solutions at 2–8 °C according to laboratory protocols.
• Avoid repeated freeze-thaw cycles to support research applications.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
2. Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. doi:10.1016/S2468-1253(23)00068-7
3. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Published 2019 Apr 12. doi:10.3389/fendo.2019.00155